Tag: poster

Årsrapport 2024/25: Bang & Olufsen rapporterer et overgangsår med rekordhøj bruttomargin, positivt driftsresultat og forbedret performance i virksomhedens brandede salgskanaler

Bang & Olufsen afsluttede året med en omsætningsvækst på 4% i 4. kvartal og et fald på 1% målt i lokal valuta for hele året, hvilket bragte den samlede koncernomsætning op på DKK 2,6 mia. Bruttomarginen fortsatte med at stige til et rekordhøjt niveau på 55,8% i 4. kvartal og 55,0% for året. For hele året udgjorde EBIT-marginen før særlige poster 1,0%, og det frie cash flow udgjorde DKK 16 mio. Overordnet set var resultatet i tråd med virksomhedens planer og på niveau med forventningerne for året.

HNSE Asia AI Hardware Battle 2025 Adds Japan Retail Showcase for Top 10 Winners; Application Deadline Extended to July 12

LINGSHUI, China, July 3, 2025 /PRNewswire/ -- The organizers of the HaiNan-Southeast Asia AI Hardware Battle (HNSE AHB) are pleased to announce an expanded prize...

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025

BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting...

Oricom and E Ink Deliver Full Color Electronic Paper Signage to Create a Sustainable Advertising Medium

The Sustainable Board is an energy efficient display medium that aligns with sustainability priorities for brands and advertisers

The Sustainable Board is an energy efficient display medium that aligns with sustainability priorities for brands and advertisers

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic^® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

The Chinese Dream: Where Fantasy Meets Reality’s Brick Wall

Ah, the Chinese Dream—a snappy slogan that promised a utopia where hard work and education would transform every peasant into a prosperous urbanite. Fast...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

Abvance presents first-in-human data on insulin-glucagon co-dosing in T1D, demonstrating a novel approach to help prevent hypoglycemia